1 UK stock I’d buy in 2022 to try to double my money

With UK stocks on the rise in 2022, Zaven Boyrazian shares his top pick from his own portfolio that could deliver triple-digit returns.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Close-up of British bank notes

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

For some UK stocks, 2022 has been a fairly decent year so far. Looking at just the FTSE 100, the index is up nearly 150 points as businesses continue to return to normality after the disruptions of the pandemic.

But not all stocks have had a great run recently. One in my portfolio has been hit particularly hard since the start of the new year. Yet despite this recent downward trajectory, I believe the company could be set for an explosive future over the long term. Let’s explore.

A rising star in the biotech sector

The biotechnology industry is renowned for its high-risk profile. Yet Oxford BioMedica (LSE:OXB) continues to impress me. At the core of this business lies the LentiVector drug development platform. Simply put, it enables large pharmaceutical companies like Novartis and Bristol Myers Squibb to develop new treatments at a lower cost.

The company generates income in the short-term through platform fees based on production milestones. But over the long term, if a drug developed on this platform makes it to market, Oxford BioMedica will receive royalties on each sale.

Only two drugs have made it to market so far, Kymriah, a treatment for blood cancer, and AstraZeneca‘s Covid-19 vaccine. But with 24 other drugs in development, the long-term potential for this biotech stock is enormous, in my opinion.

Over the last five years, revenue has grown by an average of 36% annually. And as forecasts for the gene therapy industry continue to rise, the stock of this UK biotech business has surged over 400% since 2017.

With a brand-new production-ready facility completed in 2020, the group’s capacity to take on new projects has drastically increased. And since management has already built a list of nine top-tier clients, finding these new projects should be relatively easy, in my opinion.

Taking a step back

As exciting as the growth prospects of this business may be, there are some notable risks to consider. The most prominent is the regulatory environment. Drug development is a long and arduous journey that often ends in failure. Even if a drug can make it past the regulators, its financial viability is not necessarily guaranteed.

To some extent, Oxford BioMedica is protected from this risk. After all, the company generates revenue throughout development even if a treatment eventually fails. However, if a drug doesn’t make it to market, the potential royalty income is lost, and that could cause long-term growth to stagnate.

Needless to say, a UK growth stock with wobbly growth prospects is prone to substantial volatility.

Can this UK stock double my money?

Looking at the latest half-year results, revenue for the first six months of 2021 grew by 139%, thanks to the high demand for AstraZeneca’s Covid-19 vaccine. When the pandemic ends, income from the vaccine will undoubtedly fall. But improved profit margins and newly enlisted clients, like Arcellx and Cabaletta Bio, could fill this future income void.

It seems other analysts agree with my bullish stance, with price forecasts for this UK stock at 2,400p. Compared to today’s price of 1,000p, that’s a potential gain of 140%. This is by no means guaranteed. But it does support my belief that the Oxford BioMedica share price can double in 2022. Therefore, despite the risks, I am considering adding more shares to my portfolio this year.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Zaven Boyrazian owns Oxford Biomedica. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »

Investing Articles

Are HSBC shares a FTSE bargain? Here’s what the charts say!

There are plenty of dirt-cheap FTSE 100 banking stocks for investors to choose from today. Our writer Royston Wild believes…

Read more »

Three signposts pointing in different directions, with 'Buy' 'Sell' and 'Hold' on
Investing Articles

Just released: Share Advisor’s latest ‘Hold’ recommendation [PREMIUM PICKS]

In our Share Advisor newsletter service, we provide buy, sell, and hold guidance for our universe of recommendations.

Read more »